The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report

Authors

  • Fakhri Rahman Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia
  • Harrina Erlianti Rahardjo Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia
  • Stefanus Cahyo Ariwicaksono Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia
  • Hafizar Hafizar Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia
  • Muhammad Gozali Arif Sembiring Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia
  • Rendy Andika Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia
  • Richman Patandung Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia
  • Septiani Hidianingsih Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia
  • Stevano Lucianto Hotasi Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas Indonesia

Keywords:

Docetaxel, androgen deprivation therapy, evidence-based case report, metastatic prostate cancer, overall survival

Abstract

Aim: to learn the role of docetaxel in non-castrate resistant prostate cancer patient. Methods: literature search was conducted to find relevant study comparing the combination of docetaxel and androgen deprivation therapy (ADT) to ADT alone in non-castrate resistant prostate cancer using PubMed, Cohrane Library, Proquest, EBSCO, and Scopus database. Quality assessment of studies was done using Bond University Rapid Critical Appraisal of a Systematic Review. Results: we found 494 studies from literature search, but only two studies were included in final selection. Based on validity assessment, we chose one study to be discussed further. This study showed that combination of docetaxel and ADT is better than ADT alone in regards of overall survival (HR 0.64; 95% CI 0.55, 0.75; p<0.0001; NNT=3), biochemical progression free survival (HR 0.63; 95% CI 0.57, 0.69; p<0.0001; NNT=2) and clinical progression free survival (HR 0.73; 95% CI 0.64, 0.84; p<0.0001; NNT=2). Benefit of docetaxel and ADT combination was especially seen in high volume disease (HR 0.67; 95% CI 0.54, 0.83; p=0.0003; NNT=3). Conclusion: addition of docetaxel into ADT has beneficial effects in terms of overall survival and progression free survival in patients with non-castrate resistant metastatic prostate cancer.

Downloads

Published

2017-05-10

How to Cite

Rahman, F., Rahardjo, H. E., Ariwicaksono, S. C., Hafizar, H., Sembiring, M. G. A., Andika, R., Patandung, R., Hidianingsih, S., & Hotasi, S. L. (2017). The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report. Acta Medica Indonesiana, 49(1), 74-78. Retrieved from https://www.actamedindones.org/index.php/ijim/article/view/244

Issue

Vol. 49 No. 1 (2017): Acta Medica Indonesiana

Section

SPECIAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.